Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism
Table 2
Sociodemographic and clinical features of patients and tumour characteristics according to WHO tumour classification (grading).
(a)
NET G1
NET G2
NEC
Total no. of patients ()
158 (64.0)
61 (24.7)
28 (11.3)
(b)
NET G1
NET G2
NEC
Gender ()
Male (), (%)
65 (55.1)
37 (31.4)
16 (13.6)
0.020
Female (), (%)
93 (72.1)
24 (18.6)
12 (9.3)
Age (), years (mean (SD))
58.3 (12.8)
59.8 (12.7)
63.0 (12.9)
0.176
Age at diagnosis (), years (median range)
54.7 (15-85)
56.5 (32-80)
62.5 (39-84)
0.017
Weight (), kg (mean (SD))
71.8 (13.2)
76.9 (17.5)
68.7 (10.8)
0.049
BMI (), kg·m-2 (mean (SD))
27.0 (4.6)
28.6 (5.7)
24.6 (3.1)
0.015
Comorbidities (), (%)
105 out of 147 (71.4)
44 out of 58 (75.8)
15 out of 26 (57.6)
0.233
Arterial hypertension (), (%)
29 out of 150 (19.3)
5 out of 58 (8.6)
3 out of 27 (11.1)
0.139
Diabetes mellitus (), (%)
17 out of 149 (11.4)
4 out of 58 (6.9)
1 out of 27 (3.7)
0.417
Dyslipidaemia (), (%)
15 out of 154 (9.7)
3 out of 58 (5.1)
3 out of 27 (11.1)
0.508
Cardiovascular disease (), (%)
8 out of 150 (5.3)
2 out of 58 (3.4)
1 out of 27 (3.7)
0.897
Family history of nonendocrine neoplasm (), (%)
51 out of 105 (48.6)
22 out of 42 (52.4)
6 out of 20 (30.0)
0.254
Smoking (), (%)
3 out of 110 (2.7)
4 out of 42 (9.5)
3 out of 21 (14.3)
0.007
Alcohol consumption (), (%)
38 out of 106 (35.8)
22 out of 37 (59.5)
10 out of 20 (50.0)
0.037
Tumour dimension (), mm (mean (SD))
21.3 (19.9)
32.7 (23.5)
51.7 (34.9)
<0.001
Vascular invasion (), (%)
34 out of 106 (32.1)
24 out of 41 (58.5)
9 out of 15 (60.0)
0.004
Lymphatic invasion (), (%)
39 out of 103 (37.8)
25 out of 36 (69.4)
11 out of 16 (68.7)
0.001
Perineural invasion (), (%)
26 out of 84 (31.0)
9 out of 25 (36.0)
7 out of 10 (70.0)
0.064
(c)
NET G1
NET G2
Hormonal status
Functioning ()a
17 out of 32 (53.1)
6 out of 32 (18.6)
Carcinoid ()b
8 out of 17 (47.0)
5 out of 17 (29.4)
Gastrinoma ()c
2 out of 4 (50.0)
1 out of 4 (25.0)
Insulinoma ()d
7 out of 11 (63.6)
0
Nonfunctioning, ()e
12 out of 20 (60.0)
5 out of 20 (25.0)
(d)
NET G1
NET G2
NEC
MEN-1 syndrome ()§
2 out of 137 (1.5)
2 out of 51 (3.9)
0 out of 25 (0.0)
0.575
Stage ()
Localized, (%)
51 out of 114 (44.7)
11 out of 48 (22.9)
4 out of 24 (16.7)
0.001
Locoregional, (%)
26 out of 114 (22.8)
10 out of 48 (20.8)
2 out of 24 (8.3)
Disseminated, (%)
37 out of 114 (32.5)
27 out of 48 (56.3)
18 out of 24 (75.0)
Cases missing WHO tumour classification grading: a,b,c,d, and e.§Cases reported as not presenting MEN-1 syndrome clinical features (no genetic testing was performed for unsuspicious cases).
